Company: CERO
Filing Date: 2025-07-08
Form Type: 8-K
Source: 0001213900-25-061911
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

As
previously disclosed, on June 11, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company”), received
a letter (the “ Bid Price Requirement Letter”) from the Listing Qualifications Department (the “ Staff”) at The
Nasdaq Stock Market (“ Nasdaq”) notifying the Company that, for the 30 consecutive business day period between April 25, 2025
through June 9, 2025, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “ Common Stock”)
was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2),
which is required for continued listing of the Common Stock on Nasdaq (the “ Bid Price Requirement”).

The
Company timely appealed the Staff’s delisting determination by requesting a hearing before a Hearings Panel (the “ Panel”).
Such request by the Company for a Panel hearing stayed the suspension of the Company’s securities.

On
July 7, 2025, Nasdaq informed the Company that the Staff had determined that the Company has regained compliance with the Bid Price Requirement
and is therefore in compliance with the continued listing requirements. As a result, Nasdaq canceled the hearing and the Common Stock
will continue to be listed and traded on the Nasdaq Capital Market.

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  CERO THERAPEUTICS HOLDINGS, INC.                               
  Dated: July 8, 2025                                            
  By:                                   /s/                      
  Name:                                 Chris Ehrlich            
  Title:                                Chief Executive Officer